ACCESS Newswire

AGFA HealthCare

Share
AGFA HealthCare Secures Major New Deal With Alliance Medical for a Comprehensive Cloud-Based Enterprise Imaging Solution Across the UK

MORTSEL, BELGIUM / ACCESSWIRE / June 10, 2024 / AGFA HealthCare is thrilled to announce a significant new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical's UK sites. Powered by the AGFA HealthCare Enterprise Imaging Platform, this state-of-the-art approach supports Alliance Medical UK's Future Unified Diagnostic Information System (FUDIS) project. This project aims to streamline the entire patient pathway, establishing a robust and lasting partnership between AGFA HealthCare and Alliance Medical.

To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.


Deployment of the solution will begin later in 2024, with a phased implementation approach to ensure a smooth and efficient transition of all imaging services across 120 sites for all of Alliance Medical's UK community diagnostic centres (CDCs), static imaging sites for PET-CT, MRI, CT and other imaging modalities and its extensive fleet of mobile, modular and relocatable units, delivering over 400,000 annual exams.

Efficiency gains, clinical effectiveness, and collaboration workflows
Alliance Medical has been a trusted partner to the NHS for 30 years, providing diagnostic imaging solutions to patients throughout the UK. This partnership with AGFA HealthCare will play a pivotal role in achieving the strategic vision for Alliance Medical's UK business to provide long-term, sustainable diagnostic imaging solutions on behalf of the NHS and other partners.

"The ground-breaking partnership between Alliance Medical and AGFA HealthCare will play a key role in enabling us to achieve our strategic vision, on behalf of our patients and stakeholders, and will support our commitment to integrating diagnostics into existing care pathways. AGFA HealthCare's solution really led from the front, and the digital ecosystem they brought together will deliver the experience, knowledge and innovation needed to create a complete cloud-based solution which covers the entire end-to-end patient pathway," says Pete Winchester, UK Managing Director at Alliance Medical.

"We are delighted to further strengthen our partnership with Alliance Medical Group and the relationship with Alliance Medical UK, which is an integral part of the health economy in the UK and beyond. Combining that bond with our close collaboration with our market-leading partners will enable us to jointly deliver a luminary solution that brings together each of our leading technologies: enterprise imaging, clinical decision support, complex workflow orchestration and advanced augmented intelligence. These will run through the heart of the solution to enable clinicians to deliver outcomes for patients and an exceptional user experience that is rich in efficiency gains," says Roberto Anello, Regional President for Northern Europe for AGFA HealthCare.

Transformative Technologies Delivering an Exceptional User Experience

  • The solution includes the AGFA HealthCare Enterprise Imaging Platform, with Shared Workflow and the XERO® Exchange Network (XEN):
    • Designed around scalability, connectivity and clinical collaboration, Enterprise Imaging enables near-real-time access to images and delivers powerful tools and features for diagnosis, collaboration, workflow and more. By facilitating "imaging without barriers," it supports patient and clinician work-life balance, as well as the balancing of radiologists' tasks and reporting workloads between different organisations.
    • Fully embedded artificial intelligence and advanced visualisation tools for molecular imaging all support complex clinical workflows by providing a solution that is readily available regardless of location and time.
    • The Enterprise Imaging Collaborator tool and the new Shared Workflow feature offer completely new ways of managing activity to match reporting capacity with demand, improve clinician collaboration through multi-author workflows, and align unified ‘specialist' Reporting Worklists with scarce reporting skills. The embedded XERO® application enables clinical teams to engage and share information. Enterprise Imaging is now entering the era of streaming clients capable of displaying large amounts of data in near real-time.
  • AGFA HealthCare Enterprise Imaging is powered by Amazon Web Services (AWS) cloud services, which gives Alliance Medical access to the security, reliability and scalability of the public cloud.

The platform is complemented for referrals by two market-leading solutions, including:

  • xWave Technologies' Smart Referring, an advanced portal for referring clinicians, integrated with Enterprise Imaging XERO®. xWave Smart Referring incorporates a dynamic Clinical Decision Support system which supports clinicians in accessing the most appropriate diagnostic test for their patients. Innovations such as the Smart Vetting workflow also reduce workloads for administrative and clinical staff, while improving patient safety and care.
  • Streets Heaver's Compucare® PAS/EPR (patient administration system/electronic patient record): This market-leading solution is designed for private patient workflows as well as managing NHS contracts and eReferrals. It supports all clinical activity types from general clinic consultations to diagnostic imaging workflows, as well as other non-imaging diagnostic services. Patient engagement is supported through the Patient Portal.

About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision, and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation of our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.

AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO® is a registered trademark of AGFA HealthCare N.V. All rights reserved. Compucare is a registered trademark of Streets Heaver Computer Systems Ltd. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.

Contact Information

Buse Kayar
buse.kayar@issuerdirect.com

SOURCE: AGFA HealthCare

To view this piece of content from stats.nwe.io, please give your consent at the top of this page.

View the original press release on newswire.com.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release

Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e

Ascend Advanced Therapies - ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy8.1.2026 13:00:00 CET | Press release

Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice President of Global Business Development Appointments underscore Ascend-ABL's commitment to scientific rigor, operational excellence, and strategic growth ROCKVILLE, MARYLAND / ACCESS Newswire / January 8, 2026 / Ascend Advanced Therapies - ABL Inc. today announced significant appointments to its leadership team. Seiga Ohmine Ph.D. joins as Chief Commercial Officer (CCO) Sharad Dubey CA, CPA joins as Chief Financial Officer (CFO) Patrick Lansky joins as Senior Vice President of Global Business Development These appointments reflect Ascend-ABL's focus on strengthening scientific leadership, operational discipline, and customer-centric execution as the company sharpens its positioning as a trusted CDMO partner for advanced viral modalities. Commenting on the appointments, Alessandra Rispoli, Chief Executive Officer of Ascend-ABL said, "We are making strong progress

Market Logic Announces Technology Partnership with Zappi to Accelerate Innovation with AI8.1.2026 08:00:00 CET | Press release

BERLIN, DE / ACCESS Newswire / January 8, 2026 / Market Logic Software is excited to announce a technology partnership with Zappi designed to help leading brands develop, refine, and test new product concepts faster than ever before. United by a joint agentic AI framework, this collaboration brings together advanced AI capabilities from both companies, marking a pivotal shift in how organizations execute insights-driven innovation. Through AI-to-AI integrations, linking two powerful AI platforms, enterprises can now enrich their product innovation process with a comprehensive data ecosystem. Specially trained DeepSights AI agents within Market Logic's Innovation Studio continuously monitor, analyse, and synthesize market research, news, and operational data-allowing for accelerated concept generation and more informed decision-making. With just a couple of clicks, customers can seamlessly progress to testing their concepts with real people, thanks to Zappi's real-world respondent solut

RE Royalties Announces up to a USD $9.0 Million Portfolio-Level Royalty Investment with Solaris Energy Inc.7.1.2026 22:20:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / January 7, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF) ("RE Royalties" or the "Company") is pleased to announce that it has entered into a definitive agreement with Solaris Energy Inc. ("Solaris") to invest up to USD $9.0 million to acquire a royalty interest (the "Royalty Purchase") in two portfolios of distributed generation ("DG") solar projects located throughout the United States. The first portfolio consists of 15 projects including 9 under construction with several nearing operation, and 6 in development, located across California, Maine, Delaware, New Hampshire and Colorado ("Portfolio 1"). The second portfolio comprises 9 more projects, the final composition of which may evolve as the projects advance ("Portfolio 2"). The transaction represents the acquisition of a portfolio level royalty on a diversified portfolio of DG solar assets and marks the exciting beginning of a new partnership between the two parties. The Royalty Purchase for Por

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye